CPT code 64616 represents the localized injection of a chemodenervation agent, predominantly botulinum toxin (such as Botox, Dysport, Xeomin, or Myobloc), into the musculature of the neck on a unilateral basis. This procedure is specifically designed to exclude the laryngeal muscles, which are targeted under a different code. The primary clinical application for this intervention is the management of cervical dystonia, also known as spasmodic torticollis, a painful and debilitating neurological condition characterized by involuntary muscle contractions that cause the head to twist, turn, or pull to one side. The chemodenervation agent exerts its therapeutic effect by binding to the presynaptic neuronal membrane at the neuromuscular junction, where it inhibits the release of the neurotransmitter acetylcholine. This targeted blockade interrupts the signal transmission between the nerve and the hyperactive muscle, resulting in a temporary, localized, and dose-dependent chemical denervation or paralysis. The reduction in muscle overactivity alleviates the abnormal posturing and severe pain associated with the dystonia. During the procedure, the physician identifies the specific offending muscles - most commonly the sternocleidomastoid, splenius capitis, trapezius, or levator scapulae - through physical examination and functional assessment. Due to the complex anatomical overlay of the neck and the necessity of precise injection to avoid collateral weakness or dysphagia, the provider frequently employs adjunctive guidance modalities. Electromyography (EMG) or ultrasound guidance is often utilized to confirm accurate needle placement within the belly of the target muscle prior to the delivery of the agent. Once the needle position is verified, the calculated dose of the reconstituted toxin is systematically injected. Careful post-procedural monitoring is performed to ensure there are no immediate adverse reactions, such as unintended diffusion of the toxin causing swallowing difficulties. Clinicians must meticulously document the specific muscles injected, the exact dosage administered, the unilateral or bilateral nature of the treatment, and the medical necessity supporting the use of the agent to ensure comprehensive coding and compliance. This level of detail is critical not only for substantiating the use of the specific CPT code 64616 but also for ensuring correct reimbursement of the costly pharmacological agents employed. Healthcare providers should continuously verify the expiration dates of the toxins and accurately calculate any discarded amounts to comply with single-use vial billing policies utilizing the JW modifier. The multifaceted nature of this procedure highlights the necessity for advanced anatomical knowledge and specialized training in both identifying the correct muscular targets and successfully administering the neurotoxin without compromising adjacent vital structures.